Last reviewed 2026-05-20 · How we verify

IOPYDOL

Phase 2 active Small molecule ✓ Verified May 2026

IOPYDOL is a iopydol drug. It is currently in Phase 2 development.

Iopydol is a small molecule that works by interacting with a specific target in the body.

Iopydol is a small molecule drug of the iopydol class, but specific details about its development, ownership, and commercial status are not available. Its target and mechanism of action are also unknown. As a result, there is limited information available about its approved indications, half-life, bioavailability, and generic manufacturers. Iopydol's safety profile and potential side effects are also unclear. Further research is needed to fully understand this medication.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	IOPYDOL
Drug class	iopydol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Iopydol is a key that fits into one of those locks. When it binds to the lock, it can either turn the lock on or off, depending on the type of lock and the key's shape. This interaction can help regulate various bodily functions, but the exact details of how Iopydol works are not yet fully understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IOPYDOL CI brief — competitive landscape report
IOPYDOL updates RSS · CI watch RSS

Frequently asked questions about IOPYDOL

What is IOPYDOL?

IOPYDOL is a iopydol drug.

How does IOPYDOL work?

Iopydol is a small molecule that works by interacting with a specific target in the body.

What drug class is IOPYDOL in?

IOPYDOL belongs to the iopydol class. See all iopydol drugs at /class/iopydol.

What development phase is IOPYDOL in?

IOPYDOL is in Phase 2.

Drug class: All iopydol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing